An Exploratory SPECT Imaging Study to Assess the Utility of High-specific Activity 99mTc-HMPAO Labeling as a Tool to Detect PBMC and Lymphocyte Trafficking in the Small Bowel or Ileo-caecal Region of Crohn's Disease Patients

Using scintigraphic imaging including planar scintigraphy and SPECT, this study will evaluate the utility of two different ex vivo 99mTc-HMPAO labelled mononuclear cell populations in order to select the optimal methodology (using PBMC or purified lymphocyte subpopulations) for future drug intervention studies in Crohn's disease.
Two parallel exploratory approaches will be investigated to enrich for lymphocyte populations expressing leukocyte trafficking inhibitors. In the first, whole blood will be fractionated on a ficoll gradient to purify a heterogeneous population of all the peripheral blood mononuclear cells (PBMC) for labelling. Secondly, further enrichment will be attempted using depletion of PBMC fractions of monocytes and B cells.

Start Date01 Jan 2010

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with Technetium tc-99m exametazime

100 Translational Medicine associated with Technetium tc-99m exametazime

100 Patents (Medical) associated with Technetium tc-99m exametazime

221

Literatures (Medical) associated with Technetium tc-99m exametazime

01 Mar 2024·Journal of Nuclear Medicine

Triggered Seizures for Ictal SPECT Imaging: A Case Series and Feasibility Study

Article

Author: Wiest, Roland ; Barlatey, Sabry L ; Friedrichs-Maeder, Cecilia ; Nowacki, Andreas ; Baud, Maxime O ; Schindler, Kaspar ; Mignardot, Camille G ; Pollo, Claudio ; Rominger, Axel ; Haenggi, Matthias ; Z'Graggen, Werner J ; Pyka, Thomas

Ictal SPECT is an informative seizure imaging technique to tailor epilepsy surgery. However, capturing the onset of unpredictable seizures is a medical and logistic challenge. Here, we sought to image planned seizures triggered by direct stimulation of epileptic networks via stereotactic electroencephalography (sEEG) electrodes. Methods: In this case series of 3 adult participants with left temporal epilepsy, we identified and stimulated sEEG contacts able to trigger patient-typical seizures. We administered ^99mTc-HMPAO within 12 s of ictal onset and acquired SPECT images within 40 min without any adverse events. Results: Ictal hyperperfusion maps partially overlapped concomitant sEEG seizure activity. In both participants known for periictal aphasia, SPECT imaging revealed hyperperfusion in the speech cortex lacking sEEG coverage. Conclusion: Triggering of seizures for ictal SPECT complements discrete sEEG sampling with spatially complete images of early seizure propagation. This readily implementable method revives interest in seizure imaging to guide resective epilepsy surgery.

01 Nov 2021·Clinical Nuclear MedicineQ3 · MEDICINE

No Evidence to Favor 99mTc-HMPAO or 99mTc-ECD for Ictal Brain Perfusion SPECT for Identification of the Seizure Onset Zone

Q3 · MEDICINE

Article

Author: Stodieck, Stefan ; Jaber, Mariam ; Apostolova, Ivayla ; Lanz, Michael ; Sauvigny, Thomas ; Voges, Berthold ; Lindenau, Matthias ; Martens, Tobias ; Klutmann, Susanne ; House, Patrick M ; Buchert, Ralph ; Taherpour, Jila

PurposeIctal brain perfusion SPECT with the tracer 99mTc-HMPAO or 99mTc-ECD is widely used for identification of the epileptic seizure onset zone (SOZ) in presurgical evaluation if standard pointers are uncertain or inconsistent. For both tracers, there are theoretical arguments to favor it over the other for this task. The aim of this study was to compare the performance of ictal brain perfusion SPECT between 99mTc-HMPAO and 99mTc-ECD in a rather large patient sample.Patients and MethodsThe study retrospectively included 196 patients from clinical routine in whom ictal perfusion SPECT had been performed with stabilized 99mTc-HMPAO (n = 110) or 99mTc-ECD (n = 86). Lateralization and localization of the SOZ were obtained by the consensus of 2 independent readers based on visual inspection of the SPECT images.ResultsThe 99mTc-HMPAO group and the 99mTc-ECD group were well matched with respect to age, sex, age at first seizure, duration of disease, seizure frequency, history of previous brain surgery, and findings of presurgical MRI. The proportion of lateralizing ictal SPECT did not differ significantly between 99mTc-HMPAO and 99mTc-ECD (65.5% vs 72.1%, P = 0.36). Sensitivity of ictal perfusion SPECT (independent of the tracer) for correct localization of the SOZ in 62 patients with temporal lobe epilepsy and at least worthwhile improvement (Engel scale ≤ III) 12 months after temporal epilepsy surgery was 63%.ConclusionsThis study does not provide evidence to favor 99mTc-HMPAO or 99mTc-ECD for identification of the SOZ by ictal perfusion SPECT.

21 Mar 2021·Physics in Medicine & BiologyQ2 · ENGINEERING & TECHNOLOGY

Automatic attenuation map estimation from SPECT data only for brain perfusion scans using convolutional neural networks

Q2 · ENGINEERING & TECHNOLOGY

Article

Author: Beekman, Freek J ; Goorden, Marlies C ; Chen, Yuan

AbstractIn clinical brain SPECT, correction for photon attenuation in the patient is essential to obtain images which provide quantitative information on the regional activity concentration per unit volume (kBq.

ml−1

). This correction generally requires an attenuation map (

map) denoting the attenuation coefficient at each voxel which is often derived from a CT or MRI scan. However, such an additional scan is not always available and the method may suffer from registration errors. Therefore, we propose a SPECT-only-based strategy for

map estimation that we apply to a stationary multi-pinhole clinical SPECT system (G-SPECT-I) for 99mTc-HMPAO brain perfusion imaging. The method is based on the use of a convolutional neural network (CNN) and was validated with Monte Carlo simulated scans. Data acquired in list mode was used to employ the energy information of both primary and scattered photons to obtain information about the tissue attenuation as much as possible. Multiple SPECT reconstructions were performed from different energy windows over a large energy range. Locally extracted 4D SPECT patches (three spatial plus one energy dimension) were used as input for the CNN which was trained to predict the attenuation coefficient of the corresponding central voxel of the patch. Results show that Attenuation Correction using the Ground Truth

maps (GT-AC) or using the CNN estimated

maps (CNN-AC) achieve comparable accuracy. This was confirmed by a visual assessment as well as a quantitative comparison; the mean deviation from the GT-AC when using the CNN-AC is within 1.8% for the standardized uptake values in all brain regions. Therefore, our results indicate that a CNN-based method can be an automatic and accurate tool for SPECT attenuation correction that is independent of attenuation data from other imaging modalities or human interpretations about head contours.

100 Deals associated with Technetium tc-99m exametazime

External Link

KEGG	Wiki	ATC	Drug Bank
-	Technetium tc-99m exametazime	V09AA01	DB09163

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Inflammatory Bowel Diseases	US	Jubilant Draximage, Inc.Startup	17 Aug 2017
Intraabdominal Infections	US	Jubilant Draximage, Inc.Startup	17 Aug 2017
Diagnostic agents	US	GE Healthcare, Inc.	30 Dec 1988

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Crohn Disease	Preclinical	NL	GSK Plc	01 Jan 2010
Crohn Disease	Preclinical	BE	GSK Plc	01 Jan 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Technetium tc-99m exametazime

Overview

Basic Info

Structure

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation